Chinese team finds antibody that can block new coronary infection

May 18 (Xinhua Peng Xi) Chinese scientific research team recently published a paper in the U.Sjournal Science, said they found two can effectively block the new coronavirus infection of human-derived monoclonal antibodies, is expected to be used in the development of anti-new coronary drugs and vaccinesthe Chinese Capital Medical University, the Institute of Microbiology of the Chinese Academy of Sciences, the Tianjin Institute of Industrial Biotechnology of the Chinese Academy of Sciences, shenzhen Third People's Hospital and other institutions participated in the studyThe researchers isolated four human-derived monoclonal antibodies from peripheral blood mononucleiacic cells in a new coronary patientExperiments show that these four antibodies have the neutral ity and ability to new coronavirusesTwo antibodies, called B38 and H4, respectively, can block the binding domain of the receptor of the neo-coronavirus protoprotein and its receptor, angiotensin conversion enzyme 2 (ACE2)several previous studies that have revealed the mechanism of neo-coronavirus infection, the virus is primarily infected through its surface protrusion protein receptor binding domain and ACE2 binding on human cellsExperiments showed that B38 and H4 respectively identified different epitopes of the receptor binding domain, and mouse experiments confirmed that the two antibodies could reduce the amount of virus in the lungs of infected mice, showing therapeutic effectThe two antibodies can also be mixed to more effectively suppress viral infectionsthe research team further analyzed the compound structure formed by the binding region of the new coronavirus protrusion protein receptor and B38, thus revealing the molecular mechanism of B38 to block viral infectionresearchers say new research suggests that the two antibodies screened have the potential to be further developed to treat new coronavirus infections and provide a basis for vaccine designAt present, two antibodies have been in the relevant companies for product conversion, the future is expected to be used in the clinical treatment of new corona patients.